3 ms·
You can't paint the entire pharmaceutical market as non-competitive. It really depends on the drug. Most of the egregious examples of raising prices happens i
by refurb 7y ago
You can't paint the entire pharmaceutical market as non-competitive. It really depends on the drug.
Most of the egregious examples of raising prices happens in specific markets - ones where there are significant barriers to competition even in the absence of patent protection. These markets also tend to be on the smaller side - big enough to make a good profit, but not so big that it attracts a ton of competitors.
There are examples of drug prices coming down because of competition. Hepatitis C drugs are a great example. Launched at almost $90K, they now hover around $40K because there are multiple companies competing on price (the drugs are all very effective).
The other thing driving prices down are the insurance companies. Amgen dropped the price of their cholesterol drug Repatha by 60% because insurance companies said "yeah, we're not going to pay for that at that price".[1]
[1]https://www.biopharmadive.com/news/amgen-cuts-us-repatha-price-60-amid-market-pressure/540517/ https://www.biopharmadive.com/news/amgen-cuts-us-repatha-pri...
- fucking_tragedy 7y ago> There are examples of drug prices coming down because of competition. Hepatitis C drugs are a great example. Launched at almost $90K, they now hover around $40K because there are multiple companies competing on price (the drugs are all very effective). That price is less than $500 in India. Generics in the US are estimated to cost the consumer $200[1]. [1] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4946692/ https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4946692/
- refurb 7y agoThat's because the drug is priced based on relative purchasing power. If the drug cost $500 in the US, it would have been a net loss investment in the first place.